Trial Profile
RTG113388, a Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects With Partial Onset Seizures (≥ 12 Years Old) and Subjects With Lennox-Gastaut Syndrome (≥12 Years Old)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Jan 2024
Price :
$35
*
At a glance
- Drugs Retigabine (Primary)
- Indications Lennox-Gastaut syndrome; Partial epilepsies
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies.
- 13 Mar 2014 According to the ClinicalTrials.gov record, status changed from suspended to discontinued.
- 13 Sep 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.